Yoichi Mashimo

Yoichi Mashimo

Auto-generated profile, based on publicly available information

Yoichi Mashimo

Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RNRyosuke Nakamura
Ryosuke Nakamura
TOTakeshi Ozeki
Takeshi Ozeki
NHNoriaki Hirayama
Noriaki Hirayama
ASAkihiro Sekine
Akihiro Sekine
TYTaiki Yamashita
Taiki Yamashita
EMEishin Morita
Eishin Morita

2 November 2022 in Journal of Infection
Verified
Journal Article
Closed access
YMYoichi Mashimo
Yoichi Mashimo
KYKeiko Yamazaki
Keiko Yamazaki
TKTakahiro Kageyama
Takahiro Kageyama
STShigeru Tanaka
Shigeru Tanaka
TTToshibumi Taniguchi
Toshibumi Taniguchi
YOYoshihiro Onouchi
Yoshihiro Onouchi

30 October 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KFKoya Fukunaga
Koya Fukunaga
ETEri Tsukagoshi
Eri Tsukagoshi
MKMaiko Kurata
Maiko Kurata
YMYoshiko Mizukawa
Yoshiko Mizukawa
HNHiroyuki Niihara
Hiroyuki Niihara
YSYoshiro Saito
Yoshiro Saito

17 October 2012 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
FYFumiya Yamaide
Fumiya Yamaide
SUSiizkhuu Undarmaa
Siizkhuu Undarmaa
YMYoichi Mashimo
Yoichi Mashimo
NSNaoki Shimojo
Naoki Shimojo
TATakayasu Arima
Takayasu Arima
YSYoichi Suzuki
Yoichi Suzuki
Background: Matrix metalloproteinase 12 gene (MMP12) has been shown to be associated with asthma in a Caucasian population. In this study, we investigate whether single-nucleotide polymorphisms (SNPs) of MMP12 are associated with a risk for asthma in a Japanese population. Methods: We tested for an association between SNPs in MMP12 and asthma, including its severity, in a Japanese population (630 pediatric and 417 adult patients with atopic asthma and 336 children and 632 adults as controls). The rs652438 A and G variants (N357S) were generated by site-directed mutagenesis and an assay with artificial peptide substrates was used to compare two types of MMP12 activity. The effect of MMP12 inhibition with MMP12-specific small interfering RNA (siRNA) on chemokine secretion from airway epithelial cells was also tested in vitro. Results: N357S showed a p value <0.05 for childhood and combined (adult plus childhood) asthma in the dominant model [odds ratio (OR) 1.60, 95% confidence interval (CI) 1.00–2.56, p = 0.047; OR 1.40, 95% CI 1.04–1.89, p = 0.028, respectively]. This risk variant is associated with asthma severity in adult patients. In the functional assay, the minor-allele enzyme showed significantly lower activity than the major-allele enzyme. MMP12-specific siRNA suppressed IP-10 secretion from airway epithelial cells upon stimulation with IFN-β. Conclusions: Our results suggest that MMP12 confers susceptibility to asthma and is associated with asthma severity in a Japanese population. MMP12 may be associated with asthma through inappropriate attraction of leukocytes to the inflamed tissue.